Further study from an international registry including more than 6000 IBD patients reported that the combination of a TNF antagonist and thiopurine was associated with a significantly increased risk of hospitalization or death but not with severe SARS-CoV-2 outcomes [89]. Here, TNF is linked to inflammatory bowel disease.